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E-mail address: rafael.roesler@pq.cnpq.br (R. RoesThe clinical success of targeted treatment of colorectal cancer (CRC) is often limited by resistance to anti-epi-
dermal growth factor receptor (EGFR) therapy. The neurotrophin brain-derived neurotrophic factor (BDNF)
and its receptor TrkB have recently emerged as anticancer targets, and we have previously shown increased
BDNF levels in CRC tumor samples. Here we report the ﬁndings from in vitro experiments suggesting that
BDNF/TrkB signaling can protect CRC cells from the antitumor effects of EGFR blockade. The anti-EGFR
monoclonal antibody cetuximab reduced both cell proliferation and themRNA expression of BDNF and TrkB
in human HT-29 CRC cells. The inhibitory effect of cetuximab on cell proliferation and survival was counter-
acted by the addition of human recombinant BDNF. Finally, the Trk inhibitor K252a synergistically enhanced
the effect of cetuximab on cell proliferation, and this effect was blocked by BDNF. These results provide the
ﬁrst evidence that increased BDNF/TrkB signaling might play a role in resistance to EGFR blockade. More-
over, it is possible that targeting TrkB could potentiate the anticancer effects of anti-EGFR therapy.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Resistance to epidermal growth factor receptor (EGFR)-targeted
monoclonal antibodies poses a limitation for the therapy of colo-
rectal cancer (CRC). Much recent research has focused on charac-
terizing the molecular mechanisms of acquired resistance to the
anti-EGFR antibody cetuximab. In CRC, these mechanisms include
mutations in the KRAS, BRAF, or NRAS genes, which might compen-
sate for EGFR blockade by stimulating the mitogen-activated pro-
tein kinase (MAPK) pathway [1–4]. It is also likely that resistance
can be mediated by ampliﬁcation of other receptor tyrosine ki-
nases (RTKs), as has been demonstrated for other members of
the HER (ErbB) family such as HER2 [5–7]. The identiﬁcation of
additional resistance mechanisms may reveal new avenues to in-
crease the effectivity of EGFR inhibitors.
Signaling mediated by the prototypical neurotrophin, brain-de-
rived neurotrophic factor (BDNF), which acts by activating the RTK
TrkB, has recently emerged as an anticancer target [8–10]. In CRC,
mutations have been found in two sites of the TrkB kinase domainlsevier OA license. 
rmacology and Neural Tumor
asic Health Sciences, Federal
legre, RS, Brazil. Fax: +55 51
ler).[11], and we [12] and others [13] have recently described increased
levels of BDNF in CRC tumor samples and cultured cells. Interest-
ingly, our previous ﬁndings indicated that BDNF/TrkB signaling
might play a role in resistance against an antitumor peptide that
blocks gastrin-releasing peptide receptor (GRPR), through a mech-
anism dependent on EGFR [12]. Here, we show for the ﬁrst time
that cetuximab treatment in cultured human colon cancer cells
in vitro is associated with a reduction in the expression of both
BDNF and TrkB. Importantly, BDNF could protect from the effects
of cetuximab on cell growth, and inhibiting TrkB increased the sen-
sitivity to cetuximab. These ﬁndings provide the ﬁrst evidence that
BDNF/TrkB signaling might play a role in resistance to EGFR block-
ade, and that TrkB inhibition can potentiate the antitumor effects
of anti-EGFR therapy.2. Materials and methods
2.1. Cell culture and treatments
The HT-29 human colorectal cancer cell line was obtained from
the American Type Culture Collection (Rockville, Md., USA) in 2000.
Cells were seeded (7  103 cells per well) in 96-well polystyrene
tissue culture-treated ﬂat-bottom microtiter plates (TPP, Switzer-
land) in RPMI 1640 (LGC Biotechnology, Cotia, Brazil) medium
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Brazil), gentamicin (4 mg/ml; Nova Pharma, Jardim Anápolis, Bra-
zil), ampicilin (50 mg/ml; Nova Pharma, Jardim Anápolis, Brazil),
and fungizone (250 mg/kg; GIBCO, Grand Island, USA). Cells were
kept at a temperature of 37 C, a minimum relative humidity of
95%, and an atmosphere of 5% CO2 in air. The cells were seeded
at a density of 1  104 cells/well in RPMI 10% FBS into 24-well (cell
counting experiments) or 7  103 cells per well in 96-well (MTT as-
say experiments) plates and allowed to grow for 24 h [12].
The medium was replaced and cells were treated with cetux-
imab (0.1, 1.0, or 10 nm; C225; Merck, Darmstadt, Germany) or
medium for 24 h, after which, in the cells in the BDNF co-treatment
groups, human recombinant BDNF (10 ng/ml; Sigma–Aldrich, St.
Louis, Mo., USA) was added for 48 h. For the evaluation of the co-
treatment between cetuximab (0.1 nM) and K252 (10 nM; Sig-
ma–Aldrich, St Louis, USA) cells were seeded in RPMI 1640 10%
FBS for 24 h, followed by the treatment for 72 h. The doses of
agents were chosen on the basis of pilot dose curves previous
experiments [12].
2.2. Cell proliferation and survival assays
For trypan blue cell counting, the medium was removed, cells
were washed with Hanks’ Balanced Salt Solution (Invitrogen), and
100 ll of 0.25% trypsin/EDTA solutionwas added to detach the cells,
which were counted immediately in a hemocytometer [12,14]. Pro-
liferation was also measured by MTT assay. MTT was added to each
well (11 ll; 5 mg/ml; Sigma- Aldrich, St Louis, USA), and they were
then incubated for 4 h at 37 C. The plate was left at room tempera-
ture until it was completely dry. Dimethyl sulfoxide (DMSO) was
added and the absorbancewas read at 492 nm in amultiplate reader
[12,15].
Cell survivalwasmeasuredwith a colony formation assay as pre-
viously described [12]. Cells were seeded into 6-well plates (400
cells/well) after treatment with cetuximab (0.1 or 10 nm) and BDNF
(10 ng/ml), alone or combined, for 48 h. After incubation, the cells
were replaced in RPMI 1640 medium supplemented with 10% Fetal
Bovine Serum for 7–10 days. Cells were then ﬁxedwith 70% ethanol
and counterstained with 0.5% crystal violet. Only colonies contain-
ing 50 ormore cells were scored under amicroscope. The radiation-
surviving fraction was then calculated as:
SF ¼ Number of colonies in treatment cells
Number of colonies in controls
 100Fig. 1. EGFR blockade by cetuximab dose-dependently reduces CRC cell prolifer-
ation. Cells from the HT-29 human CRC cell line were cultured and treated with
cetuximab (0.1, 1.0, or 10 nM) as described in Materials and methods. Cell
proliferation was measured with MTT assays. Data are mean ± SEM absorbance (the
lowest value among replicates in the control group was taken as 100%); n = 4
independent experiments; ⁄⁄⁄P < 0.001 compared to controls.2.3. Reverse transcriptase polymerase chain reaction (RT-PCR)
HT-29 cells were cultured in the presence of cetuximab (0.1 or
10 nm) for 10 h for RT-PCR reaction, followed by total RNA extrac-
tion using Trizol reagent (Invitrogen, São Paulo, Brazil), in accor-
dance with the manufacturer’s instructions, and reverse
transcribed with superscripttm III First-Strand Synthesis supermix
(Invitrogen). The human b-actin, BDNF, and TrkB primers were de-
signed according to the correspondingGene Bank sequence. The for-
ward and reverse primers used for RT-PCR ampliﬁcation were as
follows: BDNF, 5’-GGCTATGTGGAGTTGGCATT-3’ (forward) and 5’-
CTTCAGAGGCCTTCGTTTTG-3’ (reverse); TrkB, 5’- TGGTGCATTCCAT
TCACTGT-3’ (forward) and 5’-CGTGGTACTCCGTGTGATTG-3’ (re-
verse); b-actin, 5´-GAGACCTTCAACACCCCAG-3´ (forward) and 5´ -GC
TACAGCTTCACCAGCAG-3´ (reverse). All product sizes were 190 bp.
Semiquantitative RT-PCR conditions were optimized to deter-
mine the number of cycles that would allow product detection
within the linear phase of mRNA transcript ampliﬁcation. Experi-
ments were performed with 1.5 mm MgCl2, 0.1 lM for each pri-
mer, 0.2 mm DNTPs, 1U Taq Platinum (Invitrogen), and 2 ll
cDNA template. The expression of b-actin was measured as aninternal control. The PCR conditions for b-actin, BDNF, and TrkB
experiments were: 2.5 mm MgCl2, 0.1 lM for each primer,
0.2 mM DNTPs, 1U Taq Platinum (Invitrogen), and 1 ll cDNA tem-
plate. All assays were carried out in a total volume of 15 ll using
35 cycles for ampliﬁcation that consisted of 1 min at 95 C, dena-
turation at 94 C for 30 s, annealing at 60 C for 30 s, and extension
of primers at 72 C for 45 s, followed by a ﬁnal extension at 72 C
for 10 min. The products of b-actin (190 bp), BDNF (190 bp), and
TrkB (190 bp) were electrophoresed through 1.0% agarose gels con-
taining ethidium bromide (Biotium, Hayward, USA) and visualized
with ultraviolet light [12]. The fragments’ length was conﬁrmed
using a Low DNA Mass Ladder (Invitrogen) and the relative expres-
sion of the BDNF and TrkB gene was determined by densitometry
using freeware ImageJ 1.37 for Windows. Each experiment was
performed in replicate using RNA isolated from independent cell
cultures, and representative ﬁndings are shown. For each set of
PCR reactions, a negative control was included. Semiquantitative
data are shown as percentage changes relative to b-actin (the low-
est value among replicates in the control group was taken as 100%).
2.4. Statistics
Data are shown as means ± SEM; n = 3–6 independent experi-
ments. The lowest value among replicates in the control group
was taken as 100%. Differences between mean values were evalu-
ated by one-way analysis of variance (ANOVA) followed by Tukey
post hoc tests when appropriate. In all comparisons, P < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. The anti-EGFR monoclonal antibody cetuximab dose-dependently
reduces the proliferation of HT-29 human CRC cells
The ﬁrst experiment examined the effects of cetuximab on the
proliferation of HT-29 CRC cells. The expression of EGFR in HT-29
cells was conﬁrmed in a previous report [12]. Treatment with
cetuximab at 10, but not 0.1 or 1.0 nM, signiﬁcantly reduced the
proliferation of HT-29 cells assessed by MTT assays (P < 0.001 com-
pared to controls; Fig. 1), indicating that EGFR blockade by cetux-
imab dose-dependently inhibits the proliferation of CRC cells.
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decreased mRNA expression of BDNF and TrkB
The dose of cetuximab shown to inhibit the proliferation of HT-
29 cells in the previous experiment also produced reductions of
55.3% and 48.7%, respectively, in the mRNA expression of BDNF
(P < 0.001 compared to controls; Fig. 2A) and TrkB (P < 0.001 com-
pared to controls; Fig. 2B) assessed by RT-PCR. Cetuximab at
0.1 nM, on the other hand, produced reductions of only about 3–
4% in the expression of BDNF and TrkB mRNA, although these
reductions also were signiﬁcantly different from controls (BDNF,
P < 0.01; TrkB, P < 0.001). The results suggest that the antiprolifer-
ative effect of EGFR blockade in CRC cells involves, and possibly re-
quires, an inhibition of BDNF/TrkB signaling.3.3. BDNF protects CRC cells from the inhibitory effects of cetuximab
The addition of human recombinant BDNF (10 ng/ml) blocked
the effects of cetuximab at 10 nM on HT-29 cell proliferation as-
sessed by trypan blue cell counting (Fig. 3A). Again, treatment with
10 nM cetuximab resulted in a signiﬁcant reduction of cell prolifer-
ation (P < 0.05). However, proliferation was not inhibited, and wasFig. 2. Cetuximab reduces BDNF and TrkBmRNA expression in CRC cells. HT-29 cells
were cultured and treated with cetuximab (CTX, 0.1 or 10 nM) as described in
Materials and methods. The mRNA expression of BDNF (A) and TrkB (B) was
measured by RT-PCR. Data are mean ± SEM relative expression (% of b-actin).
Representative results are shown on the top of the graphs; n = 3 independent
experiments; ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001 compared to controls.
Fig. 3. BDNF protects CRC cells from the antitumor effects of cetuximab. HT-29 cells
were cultured and treated with cetuximab (0.1 or 10 nM), human recombinant
BDNF (10 ng/ml), or 10 nM cetuximab followed by 10 ng/ml BDNF, as described in
Materials and methods. (A) Cetuximab at 10 nM produced a signiﬁcant reduction
in cell proliferation measured by cell counting, while treatment with cetuximab
plus BDNF or BDNF alone led to an increase in proliferation. Data are mean ± SEM
cell number (% of control); n = 5 independent experiments. (B) Cetuximab at 10 nM
also reduced cell proliferation measured with MTT assays. BDNF had no effect by
itself, but proliferation was increased in cells treated with cetuximab followed by
BDNF. Data are mean ± SEM absorbance (the lowest value among replicates in the
control group was taken as 100%); n = 4 independent experiments. (C) Cell survival
assessed with a colony-forming assay was inhibited by cetuximab (10 nM), and this
effect was completely blocked by BDNF. Treatment with BDNF alone had no effect.
Data are mean ± SEM of the% surviving fraction (the lowest value among replicates
in the control group was taken as 100%); n = 4 independent experiments; ⁄P < 0.05,
⁄⁄P < 0.01, and ⁄⁄⁄P < 0.001 compared to controls.in fact enhanced compared to controls, in cells treated with 10 nM
cetuximab followed with BDNF (P < 0.05) or BDNF alone
(P < 0.001). When the MTT assay was used as a measure of cell
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(P < 0.001), and this effect was completely reversed by BDNF.
Again, proliferation was increased compared to controls in cells
treated with cetuximab plus BDNF (P < 0.001), while BDNF alone
had no effect. Cell survival measured with a colony formation assay
was signiﬁcantly reduced by BDNF (P < 0.01 compared to controls).
BDNF by itself did not affect survival, but completely protected the
cells from the effect of cetuximab (Fig. 3C). The results suggest that
BDNF can promote CRC cell proliferation and rescue from the
reduction in cell proliferation and survival produced by EGFR
blockade.
3.4. TrkB inhibition synergistically enhances the antiproliferative effect
of cetuximab in CRC cells
The previous experiments indicated that the antitumor effect of
cetuximab on HT-29 CRC cells was associated with a reduction in
BDNF and TrkB expression and blocked by the addition of exoge-
nous BDNF. In the last experiment, we examined whether, con-
versely, blocking TrkB could potentiate the effect of cetuximab.
Cells were treated with a low, ineffective dose of cetuximab
(0.1 nM), the Trk inhibitor K252a (10 nM), BDNF (10 ng/ml), cetux-
imab combined with K252a, or cetuximab combined with both
BDNF and K252a. Cell proliferation was measured with the MTT as-
say. The results are shown in Fig. 4. Neither cetuximab nor K252a
affected proliferation when given alone. However, proliferation
was reduced when the cells were treated with cetuximab com-
bined with K252a (P < 0.001). Although K252a is not a selective
TrkB inhibitor and acts also on other Trk receptors, the effect of
cetuximab plus K252a was completely abolished by BDNF, which
alone did not affect proliferation. This result suggests that TrkB
inhibition can potentiate the inhibitory effect of cetuximab on
CRC cell growth.4. Discussion
Resistance to cetuximab in patients with metastatic CRC is cur-
rently thought to be associated primarily with mutant KRAS
[1,2,16,17]. However, other mechanisms are likely to be important
as well, since up to 65% of patients bearing wild-type tumors areFig. 4. The antiproliferative effect of cetuximab in CRC cells is synergistically
enhanced by TrkB inhibition. HT-29 cells were cultured and treated with cetuximab
(10 nM), the Trk inhibitor K252a (10 nM), BDNF (10 ng/ml), cetuximab combined
with K252a, or cetuximab combined with both BDNF and K252a, as described in
Materials and methods. Cell proliferation was measured with MTT assays. Data are
mean ± SEM absorbance (the lowest value among replicates in the control group
was taken as 100%); n = 6 independent experiments; ⁄⁄⁄P < 0.001 compared to
controls.resistant to anti-EGFR antibodies [16]. Other activating mutations
in downstream effectors of EGFR signaling, such as BRAF, NRAS,
and PIK3CA (which encodes a catalytic subunit of phosphatidylino-
sitol 3-kinase, PI3 K) have been implicated [2–4,18,19].
Trk was originally described as an oncogene present in a human
colon carcinoma [20]. However, neurotrophins and Trks have been
for many years investigated mainly by neurobiologists as brain
molecules involved in neuronal survival and synaptic plasticity
[21], while their role in cancer has remained less explored. The
function of neurotrophin/Trk signaling in cancer has been mostly
characterized in neural tumors, particularly neuroblastoma. BDNF
and TrkB are preferentially expressed in aggressive neuroblasto-
mas and might stimulate tumor growth, invasion, and metastasis
[reviewed in [8–10]]. BDNF/TrkB may also promote resistance to
chemotherapy in neuroblastoma. Thus, treatment with BDNF pro-
tected neuroblastoma cells from etoposide toxicity in vitro, and
high TrkB expression in experimental neuroblastoma in mice was
associated with less sensitivity to etoposide in a xenograft mouse
model [22].
In human CRC, TrkB has been found mutated on two different
sites in its kinase domain, TRKBT695I and TRKBD751N,[11,23], but
experiments using rat epithelial cells and human tumor cell lines
have failed to provide evidence for a gain-of-function effect of
the mutations [23]. Still, it is possible that increased BDNF/TrkB
signaling plays an important role in CRC. We have recently shown
that BDNF and TrkB are expressed in CRC cell lines and sporadic
CRC specimens, and BDNF levels were increased in tumor samples
compared to non-neoplastic tissue. In addition BDNF/TrkB stimula-
tion was associated with resistance to the antitumor effects of
GRPR blockade in HT-29 CRC cells, through an EGFR-dependent
mechanism [12]. Another recent study conﬁrmed BDNF and TrkB
expression in CRC and showed that BDNF stimulated cell prolifer-
ation and had an anti-apoptotic effect mediated through TrkB [13].
Moreover, high TrkB expression in tumors has recently been asso-
ciated with poor prognosis in patients with CRC, and proliferation,
migration, and invasion in CRC cells were inhibited by TrkB knock-
down [24]. However, previous studies have not provided evidence
that BDNF/TrkB can be a mechanism of resistance to anti-EGFR
therapy in cancer. The present results provide early in vitro evi-
dence suggesting that (1) the effects of cetuximab might require
a reduction in BDNF and TrkB expression, (2) increased BDNF sig-
naling might counteract the effects of cetuximab, and (3) combined
targeting of EGFR and TrkB might increase sensitivity to anti-EGFR
therapy in CRC cells.
Further experiments will be required to identify the intracellu-
lar signaling mechanisms underlying the functional interaction be-
tween cetuximab treatment and BDNF in CRC cells. EGFR and TrkB
share common downstream effectors, including the Ras/extracellu-
lar signal-regulated protein kinase (ERK)/MAPK and the PI3 K/AKT
cascades [9,21,25]. It is possible that increased BDNF/TrkB activity
in CRC compensates for EGFR blockade by stimulating those shared
intracellular protein kinase pathways.
Our ﬁndings raise the possibility that, under conditions in
which BDNF/TrkB activity is up-regulated, as is likely the case in
CRC [12,13,24], it may contribute to cetuximab resistance. In vivo
studies aimed at investigating whether the combined targeting of
EGFR and BDNF/TrkB might be a novel strategy to overcome cetux-
imab resistance in CRC are warranted.
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